Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma

被引：0
|
作者：
Shimoni, A. [1 ]
Zwas, T. [1 ]
Oksman, Y. [1 ]
Hardan, I. [1 ]
Shem-Tov, N. [1 ]
Yerushalmi, R. [1 ]
Avigdor, A. [1 ]
Ben-Bassat, I. [1 ]
Nagler, A. [1 ]
机构：
[1] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
来源：
BONE MARROW TRANSPLANTATION | 2007年 / 39卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [1] Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma
    Shimoni, Avichai
    Zwas, S. Tzila
    Oksman, Yakov
    Hardan, Izhar
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Avigdor, Abraham
    Ben-Bassat, Isaac
    Nagler, Arnon
    [J]. EXPERIMENTAL HEMATOLOGY, 2007, 35 (04) : 534 - 540
  • [2] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
  • [3] Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Huebel, K.
    Scheid, C.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Ibritumomab tiuxetan combined with high-dose chemotherapy and autologous stem-cell transplantation (SCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma.
    Shimoni, A.
    Zwass, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Nagler, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 346S - 346S
  • [5] Ibritumomab tiuxetan (Zevalin®) combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with chemo-refractory non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S93 - S93
  • [6] Yttrium-90 ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (Zevalin-BEAM) conditioning regimen in relapsed aggressive non-Hodgkin lymphoma
    Tan, S. M.
    Lau, N. S.
    Lim, S. M.
    Zanapiah, M.
    Chang, K. M.
    [J]. BONE MARROW TRANSPLANTATION, 2008, 41 : S440 - S441
  • [7] A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
    Shimoni, Avichai
    Avivi, Irit
    Rowe, Jacob M.
    Yeshurun, Moshe
    Levi, Itai
    Or, Reuven
    Patachenko, Paulina
    Avigdor, Abraham
    Zwas, Tzila
    Nagler, Arnon
    [J]. CANCER, 2012, 118 (19) : 4706 - 4714
  • [8] Comparison between BEAM and Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-BEAM as conditioning regimen before autologous stem cell transplantation in patients with non-Hodgkin B-Cell Lymphoma
    Chic Acevedo, C.
    Garcia Torres, E.
    Llamas Poyato, M. J.
    Rodriguez, G.
    Martin, C.
    Rojas, R.
    Serrano, J.
    Tabares, S.
    Vallejo, J. A.
    Sanchez, J.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 : S224 - S224
  • [9] Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
    Krishnan, Amrita
    Nademanee, Auayporn
    Fung, Henry C.
    Raubitschek, Andrew A.
    Molina, Arturo
    Yamauchi, Dave
    Rodriguez, Roberto
    Spielberger, Ricardo T.
    Falk, Peter
    Palmer, Joycelynne M.
    Forman, Stephen J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 90 - 95
  • [10] Ibritumomab tiuxetan (Zevalin) combined with highdose chemotherapy and autologous stem-cell transplantation (SCT) in patients with chemorefractory aggressive non-Hodgkin's lymphoma
    Shimoni, A.
    Zwass, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    [J]. EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 64 - 64
12345